share_log

Benchmark Reiterates Buy on Surgery Partners, Maintains $50 Price Target

Benchmark Reiterates Buy on Surgery Partners, Maintains $50 Price Target

Benchmark重申买入手术合作伙伴,维持50美元的目标股价
Benzinga ·  05/01 11:17

Benchmark analyst Bill Sutherland reiterates Surgery Partners (NASDAQ:SGRY) with a Buy and maintains $50 price target.

基准分析师比尔·萨瑟兰重申Surgery Partners(纳斯达克股票代码:SGRY)的买入并维持50美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发